These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 38109364)

  • 1. Hepatic encephalopathy: From novel pathogenesis mechanism to emerging treatments.
    Pun CK; Huang HC; Chang CC; Hsu SJ; Huang YH; Hou MC; Lee FY
    J Chin Med Assoc; 2024 Mar; 87(3):245-251. PubMed ID: 38109364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic Encephalopathy: Diagnostic Tools and Management Strategies.
    Badal BD; Bajaj JS
    Med Clin North Am; 2023 May; 107(3):517-531. PubMed ID: 37001951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disaccharides in the treatment of hepatic encephalopathy.
    Sharma P; Sharma BC
    Metab Brain Dis; 2013 Jun; 28(2):313-20. PubMed ID: 23456517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complications of Cirrhosis in Primary Care: Recognition and Management of Hepatic Encephalopathy.
    Flamm SL
    Am J Med Sci; 2018 Sep; 356(3):296-303. PubMed ID: 30286824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of hepatic encephalopathy in the hospital.
    Leise MD; Poterucha JJ; Kamath PS; Kim WR
    Mayo Clin Proc; 2014 Feb; 89(2):241-53. PubMed ID: 24411831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on the Therapeutic Management of Hepatic Encephalopathy.
    Kornerup LS; Gluud LL; Vilstrup H; Dam G
    Curr Gastroenterol Rep; 2018 Apr; 20(5):21. PubMed ID: 29644492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nontraditional Treatment of Hepatic Encephalopathy.
    Singh J; Ibrahim B; Han SH
    Clin Liver Dis; 2024 May; 28(2):297-315. PubMed ID: 38548441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Randomized Controlled Trial Comparing the Efficacy of a Combination of Rifaximin and Lactulose with Lactulose only in the Treatment of Overt Hepatic Encephalopathy.
    Hasan S; Datta S; Bhattacherjee S; Banik S; Saha S; Bandyopadhyay D
    J Assoc Physicians India; 2018 Jan; 66(1):32-6. PubMed ID: 30341842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targets to improve quality of care for patients with hepatic encephalopathy: data from a multi-centre cohort.
    Bajaj JS; O'Leary JG; Tandon P; Wong F; Kamath PS; Biggins SW; Garcia-Tsao G; Lai J; Fallon MB; Thuluvath PJ; Vargas HE; Maliakkal B; Subramanian RM; Thacker LR; Reddy KR
    Aliment Pharmacol Ther; 2019 Jun; 49(12):1518-1527. PubMed ID: 31032966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic Review and Meta-Analysis on the Effects of Lactulose and Rifaximin on Patient-Reported Outcomes in Hepatic Encephalopathy.
    Moon AM; Kim HP; Jiang Y; Lupu G; Bissram JS; Barritt AS; Tapper EB
    Am J Gastroenterol; 2023 Feb; 118(2):284-293. PubMed ID: 36730910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term management of hepatic encephalopathy with lactulose and/or rifaximin: a review of the evidence.
    Hudson M; Schuchmann M
    Eur J Gastroenterol Hepatol; 2019 Apr; 31(4):434-450. PubMed ID: 30444745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Rifaximin Plus Lactulose with the Lactulose Alone for the Treatment of Hepatic Encephalopathy.
    Ahire K; Sonawale A
    J Assoc Physicians India; 2017 Aug; 65(8):42-46. PubMed ID: 28799305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Updates on the pathophysiology and therapeutic targets for hepatic encephalopathy.
    Alsahhar JS; Rahimi RS
    Curr Opin Gastroenterol; 2019 May; 35(3):145-154. PubMed ID: 30893082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacotherapy for hepatic encephalopathy.
    Phongsamran PV; Kim JW; Cupo Abbott J; Rosenblatt A
    Drugs; 2010 Jun; 70(9):1131-48. PubMed ID: 20518580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lactulose, rifaximin or branched chain amino acids for hepatic encephalopathy: what is the evidence?
    Gluud LL; Dam G; Borre M; Les I; Cordoba J; Marchesini G; Aagaard NK; Vilstrup H
    Metab Brain Dis; 2013 Jun; 28(2):221-5. PubMed ID: 23275147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is rifaximin better than nonabsorbable disaccharides in hepatic encephalopathy?: A meta-analysis.
    Cheng J; Chen Y; Cao W; Zuo G
    Medicine (Baltimore); 2021 Dec; 100(51):e28232. PubMed ID: 34941089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of rifaximin in the different clinical scenarios of hepatic encephalopathy.
    Coronel-Castillo CE; Contreras-Carmona J; Frati-Munari AC; Uribe M; Méndez-Sánchez N
    Rev Gastroenterol Mex (Engl Ed); 2020; 85(1):56-68. PubMed ID: 31836274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on management of patients with overt hepatic encephalopathy.
    Chacko KR; Sigal SH
    Hosp Pract (1995); 2013 Aug; 41(3):48-59. PubMed ID: 23948621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the cost-effectiveness of rifaximin-α for the management of patients with hepatic encephalopathy in the United Kingdom.
    Berni E; Murphy D; Whitehouse J; Conway P; Di Maggio P; Currie CJ; Poole C
    Curr Med Res Opin; 2018 Nov; 34(11):2001-2008. PubMed ID: 29995455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination therapy for the treatment and prevention of hepatic encephalopathy.
    Mohammad RA; Regal RE; Alaniz C
    Ann Pharmacother; 2012 Nov; 46(11):1559-63. PubMed ID: 23092866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.